Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) has a beta of 2.53. The stock’s Relative Strength Index (RSI) is 46.60, with weekly volatility at 12.12% and ATR at 0.36. The ZYNE stock’s 52-week price range has touched low of $3.12 and a $9.00 high. Its shares traded lower over the last trading session, losing -0.24% on 05/11/21. The shares fell to a low of $3.91 before closing at $4.16. Intraday shares traded counted 3.23 million, which was -20.6% lower than its 30-day average trading volume of 2.68M. ZYNE’s previous close was $4.17 while the outstanding shares total 29.32M.
Investors have identified the Drug Manufacturers – Specialty & Generic company Zynerba Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $153.25 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Zynerba Pharmaceuticals Inc. (ZYNE) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 73.37 million total, with 13.91 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -1.23 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on ZYNE sounds very interesting.
Is the stock of ZYNE attractive?
In the last 6 months, insiders have changed their ownership in shares of company stock by 2.20%.
5 out of 7 analysts covering the stock have rated it a Buy, while 2 have maintained a Hold recommendation on Zynerba Pharmaceuticals Inc.. 0 analysts has assigned a Sell rating on the ZYNE stock. The 12-month mean consensus price target for the company’s shares has been set at $7.29.